153 related articles for article (PubMed ID: 23096214)
21. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
Burke C; Alexander Grant L; Goh V; Griffin N
Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
[TBL] [Abstract][Full Text] [Related]
22. Distribution and chemical forms of gadolinium in the brain: a review.
Kanda T; Nakai Y; Hagiwara A; Oba H; Toyoda K; Furui S
Br J Radiol; 2017 Nov; 90(1079):20170115. PubMed ID: 28749164
[TBL] [Abstract][Full Text] [Related]
23. [The dynamic magnetic resonance study of focal liver lesions by FLASH sequences with bolus intravenous gadolinium-DTPA].
Olivetti L; Grazioli L; Maroldi R; Matricardi L; Milanesio L
Radiol Med; 1992 Apr; 83(4):353-60. PubMed ID: 1318558
[TBL] [Abstract][Full Text] [Related]
24. Hepatic kinetics of MRI contrast agents in the isolated perfused rat liver.
Pastor CM; Terrier F; Vallée JP
Acad Radiol; 2002 Aug; 9 Suppl 2():S455-6. PubMed ID: 12188306
[No Abstract] [Full Text] [Related]
25. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
Huang B; Liang CH; Liu HJ; Wang GY; Zhang SX
Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
[TBL] [Abstract][Full Text] [Related]
26. MRI findings of rapidly progressive hepatocellular carcinoma.
Kierans AS; Leonardou P; Hayashi P; Brubaker LM; Elazzazi M; Shaikh F; Semelka RC
Magn Reson Imaging; 2010 Jul; 28(6):790-6. PubMed ID: 20427139
[TBL] [Abstract][Full Text] [Related]
27. Can gadolinium be safely given in renal failure?
Weissleder R
AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
[No Abstract] [Full Text] [Related]
28. Hepatic haemangioma: dynamic MRI using gadolinium-DTPA.
Ohtomo K; Itai Y; Yoshikawa K; Kokubo T; Yashiro N; Iio M
Eur J Radiol; 1987 Nov; 7(4):257-9. PubMed ID: 3691543
[TBL] [Abstract][Full Text] [Related]
29. MultiHance: help or hype?
Bartolozzi C; Spinazzi A
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
31. New contrast agents for imaging the liver.
Helmberger T; Semelka RC
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
[TBL] [Abstract][Full Text] [Related]
32. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
33. [Gadolinium-DTPA dimeglumine administered orally for the study of the abdomen with magnetic resonance. Clinical evaluation and tolerance].
Squillaci E; Crecco M; Cecconi L; Lupoi D; Sergiacomi GL; Simonetti G
Radiol Med; 1993 Sep; 86(3):284-93. PubMed ID: 8210538
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.
Goodwin MD; Dobson JE; Sirlin CB; Lim BG; Stella DL
Radiographics; 2011 Oct; 31(6):1547-68. PubMed ID: 21997981
[TBL] [Abstract][Full Text] [Related]
35. [Differentiation of focal liver lesions using contrast-enhanced MRT].
Heintz P; Ehrenheim C
Rofo; 1989 Mar; 150(3):297-306. PubMed ID: 2538880
[TBL] [Abstract][Full Text] [Related]
36. Changes in signal intensity in the dentate nucleus at unenhanced T1-weighted magnetic resonance imaging depending on class of previously used gadolinium-based contrast agent.
Kasper E; Schemuth HP; Horry S; Kinner S
Pediatr Radiol; 2018 May; 48(5):686-693. PubMed ID: 29417165
[TBL] [Abstract][Full Text] [Related]
37. Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma.
Cereser L; Furlan A; Bagatto D; Girometti R; Como G; Avellini C; Orsaria M; Zuiani C; Bazzocchi M
J Comput Assist Tomogr; 2010; 34(5):706-11. PubMed ID: 20861773
[TBL] [Abstract][Full Text] [Related]
38. [Oral contrast media in the study of the esophagus with magnetic resonance. Proposal of a new preparation].
Squillaci E; Fanucci E; Crecco M; Grandinetti ML; Cecconi L; Squillaci S; Simonetti G; Mattioli M; Vitali L
Radiol Med; 1992 Dec; 84(6):761-6. PubMed ID: 1494679
[TBL] [Abstract][Full Text] [Related]
39. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration.
Morana G; Grazioli L; Kirchin MA; Bondioni MP; Faccioli N; Guarise A; Schneider G
Invest Radiol; 2011 Apr; 46(4):225-39. PubMed ID: 21102346
[TBL] [Abstract][Full Text] [Related]
40. Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial.
McClellan TR; Motosugi U; Middleton MS; Allen BC; Jaffe TA; Miller CM; Reeder SB; Sirlin CB; Bashir MR
Radiology; 2017 Feb; 282(2):361-368. PubMed ID: 27509544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
